We investigated the in vitro activity of nystatin and liposomal nystatin against 103 Candida isolates to determine the effect of both time and medium on MICs. We also compared the nystatin MICs with those of amphotericin B and fluconazole. Testing was performed in accordance with the National Committee for Clinical Laboratory Standards M27-A microdilution methodology with RPMI 1640, RPMI 1640 supplemented with glucose to 2% (RPMI-2), and antibiotic medium 3 supplemented with glucose to 2% (AM3). While nystatin MICs were similar to or slightly lower than liposomal nystatin MICs in RPMI 1640 and RPMI-2, they were markedly higher than liposomal nystatin MICs in AM3. Use of AM3 and determination of the MIC after 24 h of incubation provided a slightly wider range of liposomal nystatin MICs (0.06 to >16 g/ml). Under these conditions, the MICs at which 90% of isolates were inhibited of nystatin and liposomal nystatin were 2 and 1 g/ml, respectively. Nystatin and liposomal nystatin in general showed good activity against all Candida spp. tested. Although the MICs of nystatin and liposomal nystatin tended to rise in parallel with the amphotericin B MICs, nystatin and liposomal nystatin MICs of 1 to 2 and 0.5 to 1 g/ml, respectively, were obtained for seven and six, respectively, of nine isolates for which amphotericin B MICs were >0.25 g/ml. No correlation between fluconazole and nystatin or liposomal nystatin MICs was observed. As amphotericin B MICs of >0.25 g/ml correlate with in vitro resistance, these results suggest that liposomal nystatin might have activity against some amphotericin B-resistant isolates. In vivo testing in animal models is required for clarification of this issue.
As acquired resistance has been described for both amphotericin B and the current azoles (4, 10, 30, 31, 34) , there is interest in developing new antifungal agents. Nystatin, a polyene antibiotic derived from Streptomyces noursei, is known to be effective against a variety of fungal infections in humans. Although the drug has been widely used as oral and topical therapy for superficial mycoses (16) , intravenous use has been limited by its toxic side effects. To overcome these problems, nystatin has been reformulated in a lipid complex that has demonstrated reduced side effects while maintaining antifungal activity in vitro and in vivo 6, 9, 11, 17, 18, 32; C. J. Jessup, T. J. Wallace, and M. A. Ghannoum, Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-88, 1997).
The relevance, if any, of in vitro testing with lipid-based preparations of polyenes such as amphotericin B and nystatin (rather than the parent drug) is unclear. Some feel that the role of a lipid formulation is solely to alter in vivo drug delivery and that testing the in vitro activity of lipid formulations is of little relevance. On the other hand, use of a lipid-based polyene preparation could be viewed as simply being an alternative way to dissolve the polyene, as opposed to the use of the dimethyl sulfoxide (DMSO) specified by the National Committee for Clinical Laboratory Standards (NCCLS) methodology for these hydrophobic compounds. As the choice of solubilizing system has been shown to influence azole MICs (8) , the possible relevance of use of a lipid polyene as the drug source for in vitro testing merits investigation. In studies to date with lipid formulations of amphotericin B, the MICs of some lipid formulations were higher than those of the parent compound in some studies (11, 23, 24) , whereas similar MICs for lipid and conventional formulations were obtained by other workers (1) .
Complicating these issues is the fact that in vitro susceptibility testing of amphotericin B is technically difficult. The NCCLS M27-A methodology fails to reliably detect amphotericin B-resistant isolates (20) . Thus we (28; M. Lozano-Chiu, S. Arikan, F. M. Martin-Diez, V. Paetznick, J. L. RodriguezTudela, and J. H. Rex, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. J-18, p. 455, and J-19b, p. 456, 1998) and others (14, 21 ) explored variants of M27-A that might resolve this problem. In our hands, use of antibiotic medium 3 supplemented with glucose to 2% as the test medium and an incubation period of 24 h improved detection of in vitro resistance to amphotericin B (28; Lozano-Chiu et al., 38th ICAAC, abstr. J-18 and J-19b). However, Nguyen et al. (21) reported that MICs in antibiotic medium 3 were insensitive in predicting outcome and that the best predictor for microbiological failure was amphotericin B minimum lethal (fungicidal) concentration (MLC) at 48 h. In these workers' hands, supplementation of the medium to 2% glucose also provided no advantage over plain antibiotic medium 3 in detection of resistant isolates. These differences highlight the importance of technical factors in the measurement of amphotericin B MICs.
Based on the structural similarity between nystatin and amphotericin B, we speculated that in vitro susceptibility testing of nystatin and liposomal nystatin might present difficulties similar to those observed for amphotericin B. We now report investigations of the comparative in vitro activity of nystatin and those of liposomal nystatin, amphotericin B, and fluconazole against several Candida spp. We tried to (i) determine the in vitro activity of nystatin against Candida isolates and the influence of species, time of reading, reading method, and the test medium on nystatin and liposomal nystatin MICs; (ii) compare the in vitro activity of nystatin with those of liposomal nystatin, amphotericin B, and fluconazole; and finally (iii) determine the possibility of cross-resistance between nystatin and amphotericin B or fluconazole.
(This work was presented in part previously [S. Arikan, M. Lozano-Chiu, V. Paetznick, D. Gordon, T. Wallace, and J. H. Rex, Abstr. 98th Gen. Meet. Am. Soc. Microbiol., abstr. C-280, 1998]).
MATERIALS AND METHODS
Isolates. Three groups of Candida isolates were tested. The first group consisted of four previously defined clinical isolates for which amphotericin B MICs were relatively high (Ն0.25 g/ml) (2, 28): 5W31 (C. lusitaniae), Y537 (C. albicans), CL2887 (C. lusitaniae), and MY1012 (C. tropicalis). The second group was composed of 95 randomly selected clinical isolates and included 38 isolates of C. albicans, 17 isolates of C. glabrata, 11 isolates of C. tropicalis, 10 isolates of C. parapsilosis, 9 isolates of C. krusei, 9 isolates of C. lusitaniae, and one isolate of C. lipolytica. The third group consisted of four quality control strains (25, 26) : C. parapsilosis ATCC 22019, C. parapsilosis ATCC 90018, C. krusei ATCC 6258, and C. tropicalis ATCC 750. Identification of the strains was accomplished by standard methods (13) .
Antifungal agents. Liposomal nystatin (NYOTRAN) was obtained from Aronex Pharmaceuticals, Inc. (The Woodlands, Tex.) as a lyophilized product containing nystatin mixed with dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol (lot numbers 503-33-0010 and 503-33-0011). The product was reconstituted in sterile saline, yielding a concentration of 1 mg/ml. Once prepared, the fresh liposomal nystatin suspension was used to prepare the microdilution trays. Standard powder of nystatin was obtained from Gist-Brocades (Capua, Italy) through Aronex Pharmaceuticals and was dissolved in DMSO; the stock solution was kept at Ϫ70°C until use. Amphotericin B (Bristol-Myers Squibb, Plainsboro, N.J.) and fluconazole (Pfizer Pharmaceuticals, New York, N.Y.) were obtained from their respective manufacturers as standard powders. Stock solutions for amphotericin B were prepared by dissolving the drug in DMSO. Fluconazole was dissolved in sterile distilled water. Both solutions were stored at Ϫ70°C until use.
Drug preparation and antifungal susceptibility testing. Except as noted, the testing was performed according to the procedures for the microdilution variant of the NCCLS M27-A standard (20) . Liposomal nystatin, nystatin, amphotericin B, and fluconazole were tested in twofold dilutions on microtiter plates. The concentrations ranged from 0.03 to 16 g/ml for liposomal nystatin and nystatin, 0.078 to 4 g/ml for amphotericin B, and 0.125 to 64 g/ml for fluconazole. Dilution series were prepared in DMSO (amphotericin B and nystatin) or water (fluconazole and liposomal nystatin). Amphotericin B, nystatin, and fluconazole microtiter plates were prepared in advance and kept at Ϫ70°C until use. These are conditions under which both prior work in our laboratory and concurrent control testing demonstrated the stability of the materials. Liposomal nystatin plates were used on the day of preparation. Susceptibility to amphotericin B was determined in antibiotic medium 3 (BBL, Becton Dickinson, lot JD4ZSG) supplemented to 20 g of glucose/liter and buffered to pH 7.0 with 0.01 M phosphate (AM3) 28; Lozano-Chiu et al., 38th ICAAC, abstr. J-18). Susceptibility to nystatin and liposomal nystatin was determined in the standard NCCLS M27-A medium (RPMI 1640 with glutamine and buffered with 0.165 M MOPS [morpholinepropanesulfonic acid] [RPMI]), RPMI 1640 supplemented to 2% glucose (RPMI-2), and AM3. Fluconazole susceptibility testing was performed in RPMI. Each isolate was tested in duplicate, and four reference strains were included for quality control. MICs for reference strains were determined four times in duplicate for liposomal nystatin and once in duplicate for nystatin. Twenty-eight isolates were tested four times to establish the reproducibility of the methods.
Interpretation of the results. MICs (in micrograms per milliliter) were read both visually and by spectrophotometer. As we have previously found that determining the MIC after 24 h rather than the NCCLS M27-A-specified 48 h improves the correlation between in vitro and in vivo results for both amphotericin B (28) and fluconazole (29) , MICs were recorded after both 24 and 48 h. Visual readings were done after shaking (Minishaker; Dynatech Laboratories) the plates for 1 to 2 min (3). Spectrophotometric readings were based on the reduction of growth compared to that in a growth control well for each isolate. For this, microtiter plates were agitated and the optical densities of the wells were determined at 530 nm (model EL310 EIA Autoreader; Biotek Instruments). The background optical density of the sterility check control well was subtracted from the optical densities of all of the other wells. The resulting optical density values were divided by the optical density of the drug-free growth control well to calculate the percentage of growth compared to the growth in the growth control well (29) .
For visual readings of the nystatin, liposomal nystatin, and amphotericin B MICs, the least concentration of the drug which produced an optically clear well was recorded as the MIC. The spectrophotometric MICs of these agents were the least drug concentrations which resulted in 95% reduction in growth by spectrophotometric measurements. Reduction by 95% was found to correspond to an optically clear well and was used instead of 100% in the spectrophotometric MIC calculation to compensate for minor imperfections in the well. For fluconazole, the MIC was determined according to NCCLS M27-A procedures. As we have also observed that the MIC obtained by reading after 24 h and by using a spectrophotometric end point of 50% reduction in growth may correlate more reliably with the clinical outcome (29) , this MIC was also recorded.
Based on the previous in vitro and in vivo data (28), isolates for which the amphotericin B MICs were relatively high, defined as Ն0.25 g/ml, were considered putatively resistant to amphotericin B.
Determination of MLC values of amphotericin B and nystatin. MLC values for amphotericin B and nystatin were obtained by the method described by Nguyen et al. (21) . Briefly, after visual determination of the 48-h MIC and after shaking the microtiter plate, 25 l from each clear well was plated on Sabouraud dextrose agar and incubated at 35°C for 48 h. The MLC was taken as the concentration of the first clear well that showed no CFU growth, corresponding to the least concentration of drug which produced a Ͼ98% reduction of the initial inoculum.
RESULTS
Influence of species, time of reading, and reading method on nystatin and liposomal nystatin MICs. Nystatin and liposomal nystatin MICs for clinical and American Type Culture Collection isolates are shown in Tables 1 and 2 , respectively. There was no species-related variation of nystatin and liposomal nystatin MICs. MICs for most isolates at 48 h were twofold greater than those at 24 h. Excellent agreement between visual assessments of no growth and spectrophotometric 95%-reduction end point values was observed. At 24 h, visual and spectrophotometric readings produced identical MICs for 66 and 80 of 99 isolates tested against nystatin and liposomal nystatin, respectively. Similarly, these two reading parameters were within one twofold dilution for 94 (95%) and 98 (99%) of 99 isolates tested against nystatin and liposomal nystatin, respectively. Visual and spectrophotometric MICs were thus essentially the same, and spectrophotometric readings are reported throughout for both drugs. Finally, repetitive (n ϭ 4) testing of 28 isolates against liposomal nystatin showed that MICs varied VOL. 40, 2002 SUSCEPTIBILITY TESTING OF CANDIDA ISOLATES 1407
by one dilution or less in all three media. Similar results were obtained in duplicate testing of 10 strains against nystatin.
Comparison of nystatin and liposomal nystatin MICs. As shown in Tables 1 and 2 , nystatin and liposomal nystatin had favorable activity against all Candida spp., with the exception of some amphotericin B-resistant strains. Comparison of nystatin MICs with those of liposomal nystatin showed that the differences were medium dependent. Nystatin in general generated similar or slightly lower MICs than liposomal nystatin in RPMI and RPMI-2, but nystatin MICs were consistently and sometimes markedly higher than liposomal nystatin MICs in AM3. This effect was observed for all Candida spp. tested as well as the putatively amphotericin B-resistant isolates included in the study.
Influence of test media on nystatin MICs. Nystatin MICs in RPMI-2 were in general similar to or slightly higher than those in RPMI at both 24 and 48 h. Nystatin MIC ranges in RPMI and RPMI-2 were similarly wide for all species other than C. glabrata. AM3 consistently generated the highest nystatin MICs at both 24 and 48 h. This effect resulted in a wide nystatin MIC range in AM3, with a shift toward higher MICs.
Influence of test media on liposomal nystatin MICs.
A wider range of liposomal nystatin MICs in AM3 than in RPMI and RPMI-2 was obtained for some strains, and especially for the C. tropicalis isolates. The wider range in AM3 in general was due to generation of MICs for some isolates that were one to three twofold dilutions lower than those generated in the other two media. This observation for AM3 was less pronounced at 48 h. The numbers of isolates for which the MICs in AM3 were lower than those in RPMI were 73 and 56 at 24 and 48 h, respectively. The MIC range for AM3 at 24 h was identical with the range for RPMI for the putatively amphotericin Bresistant isolates.
Nystatin and liposomal nystatin MICs for isolates for which amphotericin B MICs are high. Based on our previous demonstrations that amphotericin B MICs determined at 24 h were most likely to be of clinical relevance and provided good discrimination of resistant isolates (28), we focused our attention on these MICs of nystatin and liposomal nystatin as well. The comparison of amphotericin B MICs with those of nystatin and liposomal nystatin in AM3 at 24 h of incubation is shown in Fig. 1 and 2 , respectively. Under these conditions, the MICs at which 90% of isolates were inhibited (MIC 90 s) of nystatin and liposomal nystatin were 2 and 1 g/ml, respectively. Amphotericin B MICs for five isolates in the group of randomly selected clinical isolates were also found to be Ն0.25 g/ml. This made a total of nine isolates which were putatively amphotericin B resistant. Relatively higher nystatin and liposomal nystatin MICs were associated with increased amphotericin B MICs. However, MICs of nystatin and/or liposomal nystatin for the isolates that were putatively resistant to amphotericin B (MIC, Ն0.25 g/ml) (2, 28) were not always elevated (Table 3) . While nystatin and liposomal nystatin MICs for two (Y537 and MY1012) and three (CL2887, Y537, and MY1012) of the nine amphotericin B-resistant isolates, respectively, were high (4 to Ͼ16 g/ml), the remaining seven and six isolates, respectively, yielded nystatin and liposomal nystatin MICs that were lower than the MIC 90 for the overall population of the corresponding drug.
Nystatin and liposomal nystatin MICs for isolates with low amphotericin B MICs. Nystatin had low MICs for 87 of 90 strains for which the amphotericin B MICs were low. Interestingly, the nystatin MICs for the remaining three isolates were higher than the MIC 90 of the drug (Fig. 1) . Unlike what was found for nystatin, low amphotericin B MICs were associated with low liposomal nystatin MICs for all isolates (Fig. 2) . Of interest, the amphotericin B MICs for all C. krusei isolates (n ϭ 9) tested were relatively high (0.125 to 0.25 g/ml). The nystatin and liposomal nystatin MIC ranges for these isolates were 1 to 4 and 0.5 g/ml, respectively. These results indicated that, for eight of nine C. krusei isolates, nystatin MICs were lower than the nystatin MIC 90 , while for all of them the liposomal nystatin MICs were lower than the liposomal nystatin MIC 90 .
Comparison of MICs with MLCs for nystatin and amphotericin B.
Comparison of MICs and MLCs for each individual isolate showed that, for 92 (92.9%) and 81 (81.8%) of the clinical isolates, the MLCs of nystatin and amphotericin B, respectively, were identical to or one twofold dilution higher than the corresponding MICs. For the remaining isolates the MLCs of nystatin and amphotericin B were at most three and four twofold dilutions higher, respectively, than the corresponding MICs. For all of these isolates the MICs were in the higher end, and for some the MLCs were Ͼ16 g/ml.
Comparison of fluconazole MICs with those of nystatin and liposomal nystatin. Comparison of the nystatin and liposomal nystatin MICs with that of fluconazole for each individual isolate showed that there was no relationship between the in vitro efficacy and MIC trend of nystatin or liposomal nystatin with fluconazole (data not shown).
DISCUSSION
With the exception of some of the putatively amphotericin B-resistant isolates, nystatin and liposomal nystatin showed good activity against our test isolates. Data reported by others on in vitro activity of liposomal nystatin against Candida isolates are similar to our results. No set of MICs for any of the Candida spp. tested were consistently high, and nystatin and liposomal nystatin MICs for each of the species tested were comparable. In terms of nystatin and liposomal nystatin MIC end points, we initially determined the concentrations which resulted in complete visual inhibition of growth (MIC-0) and 95% inhibition as detected by spectrophotometer. These end points were chosen based on the fungicidal activity of the parent drug, which we have confirmed by MLC determinations, the ability of the drug to give clear end points without significant trailing and its being similar to the end point used for determining amphotericin B MICs. As expected, the visual MIC-0 values were in excellent agreement with MICs from the spectrophotometric 95% reduction for both drugs, and we reported our spectrophotometric readings.
The major modifications we made in the standard NCCLS method were related to the test media and the incubation period. The current NCCLS recommendations for antifungal susceptibility testing of yeasts involve the use of RPMI and a 48-h incubation period (20) . RPMI-2 and AM3 were also tested in the present study, and the MICs were evaluated at 24 h of incubation as well as 48 h. Our data show that addition of 2% glucose to standard RPMI 1640 did not alter the nystatin On the other hand, comparison of the in vitro activity of the parent compound, nystatin, with that of its lipid formulation, liposomal nystatin, also showed that the test medium influenced the results. The influence of AM3 on nystatin MICs and that on liposomal nystatin MICs were completely opposite. Nystatin-AM3 MICs were higher than those of nystatin-RPMI and nystatin-RPMI-2 in general. In contrast, liposomal nystatin-AM3 MICs were lower than those of liposomal nystatin-RPMI and liposomal nystatin-RPMI-2. These results suggest that the incorporation of nystatin into liposomes somehow resulted in generation of lower AM3 MICs. However, whether the use of AM3 falsely elevated the nystatin MICs or falsely lowered the liposomal nystatin MICs is not clear. The clinical significance of this finding is also unknown.
Determination of the in vitro activity of nystatin and liposomal nystatin against amphotericin B-resistant isolates was the other major objective of our study. Of nine isolates for which amphotericin B MICs were Ն0.25 g/ml, the MICs of nystatin and liposomal nystatin for seven and six, respectively, in AM3 at 24 h were low. Despite the structural similarity between amphotericin B and nystatin, cross-resistance between the two drugs is thus not a certainty. Differences between polyenes have also been reported by others (4, 10, 34) . Our results suggest that nystatin and its lipid formulation might show a favorable activity against some of the isolates resistant to amphotericin B, although this will require validation in an in vivo system. Our other significant observation was the relatively high amphotericin B MICs for all of the C. krusei isolates tested. Supporting this concept are other reports of relatively high amphotericin B MICs for C. krusei isolates (J. H. Rex, M. Lozano-Chiu, V. Paetznick, A. T. Khyne, S. Nangia, A. Arizmendi, L. Riser, P. G. Pappas, and Coinvestigators of the NIAID MSG Candidiasis Subproject, Program Abstr. 36th Annu. Meet. Infect. Dis. Soc. Am., abstr. 324,1998), reports of failure of amphotericin B in treatment of C. krusei infection in mice (12) , and demonstrations of the inability of amphotericin B to decrease the fungal burden of the kidneys (7). Moreover, systemic C. krusei infections, especially those in association with neutropenia, have been reported to be difficult to treat with amphotericin B (15, 19, 22) . We detected relatively low nystatin and liposomal nystatin MICs for most of the C. krusei isolates tested. Liposomal nystatin thus might provide improved activity against infections due to C. krusei. The lack of correlation between the MICs of fluconazole and liposomal nystatin was not surprising, given the different structures and mechanisms of action of these two antifungal agents.
On the other hand, our finding of high nystatin MICs for some of the amphotericin B-susceptible isolates was striking and supported the concept that amphotericin B susceptibility is not always associated with nystatin susceptibility. Analysis of this finding together with the previously noted nystatin susceptibility of amphotericin B-resistant isolates showed that variability of the in vitro activities of these agents might operate in both directions. Similarly, in vitro activities of nystatin and liposomal nystatin are not always the same. These findings suggest that, although nystatin, amphotericin B, and liposomal nystatin are all polyenes, variations in their in vitro efficacies against clinical Candida isolates are possible. Whether these in vitro differences have in vivo implications requires clinical investigations.
In summary, we have confirmed that nystatin and liposomal nystatin are similarly active in vitro against a variety of Candida species. Relatively low liposomal nystatin MICs obtained for some amphotericin B-resistant isolates are particularly noteworthy. Further investigations focusing on determination of breakpoint values and the in vivo activity of liposomal nystatin in infections due to amphotericin B-resistant Candida isolates are required.
